Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leuprolide + tamoxifen + trastuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intramuscular, Oral, Intravenous
01
Overview
A combination therapy consisting of leuprolide (a luteinizing hormone-releasing hormone analog), tamoxifen (a selective estrogen receptor modulator), and trastuzumab (a HER2-targeted monoclonal antibody). This regimen is used primarily for the treatment of hormone receptor-positive (HR+) and HER2-positive breast cancer in premenopausal women. The combination works through multiple mechanisms: leuprolide suppresses ovarian function and reduces estrogen production, tamoxifen blocks estrogen receptors in breast tissue, and trastuzumab targets the HER2 protein overexpressed in certain breast cancers.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)GnRHR (Gonadotropin-releasing hormone receptor)ER (Estrogen receptor)
Beyond the preview
Go deeper on leuprolide + tamoxifen + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leuprolide + tamoxifen + trastuzumab.